Jason Kelly

Ginkgo is going public via a SPAC at a $15 billion valuation. But it's pitching investors revenue growth beyond other synthetic-biology companies.

Ginkgo Bioworks is now worth $4 billion after a $290 million capital infusion that will give the company the cash to dramatically expand its developer shop for genetic programming. The Boston-based company is one of a handful of U.S.-based early-stage companies that are on the forefront of developing the tools to modify genetic material for [...]

Kambr plans to build revenue management software that big airlines can use to monitor how people buy airline flights.

Ginkgo's Motif Ingredients, which aims to replicate animal protein for meatless alternatives, is getting $90 million from Breakthrough Energy, others.